Clinical Trials Sponsored by Alphamab Jilin Co., Ltd.

Total 86 results

Alphamab Jilin Co., Ltd.

Unknown

Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women

Infertility, Female
Alphamab Jilin Co., Ltd.

Unknown

Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers

Infertility, Female

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Thymic Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Unknown

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Advanced Solid Tumor

Australia
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
Alphamab (Australia) Co Pty Ltd.

Recruiting

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Australia
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Advanced Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

Squamous Non-small-cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
Alphamab (Australia) Co Pty Ltd.

Unknown

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

HER2 Positive Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Peking University

Completed

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

HER2-positive Solid Tumors

China
Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Recruiting

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand
Maoxiang Group Jilin Pharmaceutical Co., Ltd.

Completed

The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

China
Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
The First Hospital of Jilin University
Geneplus-Beijing Co. Ltd.

Recruiting

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Endometrial Cancer

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Jilin Provincial Tumor Hospital

Recruiting

A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors

Locally Advanced Unresectable Carcinoma

China
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Osteosarcoma
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Fujian Akeylink Biotechnology Co., Ltd.
The First Hospital of Jilin University

Recruiting

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets

Pharmacokinetics | Food Affect | Single Ascending Dose | Maximum Applicable Dose

China
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Guangzhou JOYO Pharma Co., Ltd
The First Hospital of Jilin University

Completed

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic

Hypercholesterolemia

China
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Hepatic Impairment

China
Sichuan Huiyu Pharmaceutical Co., Ltd
The First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaborators

Completed

Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

Iron Deficiency | Anaemia

China
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
The First Hospital of Jilin University

Recruiting

A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB (HTS)

Pharmacokinetics | Efficacy | Safety

China
The First Hospital of Jilin University
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

Primary Liver Cancer Early Detection (PRIMe-liver)

Liver Cancer

China
Grand Life Science (Liaoning) Co., Ltd.
The First Hospital of Jilin University

Recruiting

To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder

Hyperphosphatemia

China
Yi Yang
Shineway Pharmaceutical Co.,Ltd

Completed

Effectiveness and Safety of Yiqitongluo Granule for Stroke

Stroke
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
The First Hospital of Jilin University

Recruiting

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma (MB07133)

Tolerance | Safety Issues | Effect of Drug

China

Clinical Trials Sponsored by Alphamab Jilin Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations